Biotech Acquisition Return on Equity

Biotech Acquisition (BIOT) currently reports a ROE of -100.9%. That is below the sector sector average of -5.68%. Use the charts on this page to explore Biotech Acquisition's ROE history and peer comparisons.

Biotech Acquisition's ROE of -100.9% is lower than the its sector sector average of -5.68%. That is roughly 1675.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Biotech Acquisition's current -100.9% should be judged against industry norms (sector average: -5.68%) and against BIOT's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -100.9%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is -5.68%. From there, open related valuation or income-statement pages for Biotech Acquisition, and consider following BIOT for alerts when major investors trade the stock.